Search

Showing total 34 results
Start Over Topic hybridon inc.
34 results

1. Sense and Antisense in Biotech: The First Antisense DNA Company.

Author

Pederson, Thoru

Subjects
ANTISENSE DNA, BIOTECHNOLOGY industries
Abstract

The article profiles the biotechnology company Gilead Science. It highlights the contributions of scientist Paul Zamecnik and business strategist Michael Riordan to the field of antisense DNA. The author recounts his personal experiences establishing and managing Hybridon with Zamecnik. He also commends Zamecnik and Riordan for their efforts to examine and promote the use of antisense DNA.

Published
2012
Full Text
View/download PDF

3. Hybridon Publishes Preclinical Data on New Immunomodulatory Oligonucleotide Design that Stimulated Production of Interferon-Alpha and Proliferation of B-Cells

Subjects
Hybridon Inc., Biotechnology industry, Business, News, opinion and commentary
Abstract

Hybridon, Inc. (BULLETIN BOARD: HYBN.OB) announced the publication of a paper that illustrates a novel approach to the design of immunomodulatory oligonucleotide (IMOTM) compounds that promote human B-cell proliferation as [...]

Published
2003

5. Preclinical data on Mdm2 antisense oligonucleotide published

Subjects
Hybridon Inc., Biotechnology industry, Health, Pharmaceuticals and cosmetics industries
Abstract

2003 OCT 31 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN) announced the publication of a paper on an Mdm2 antisense oligonucleotide in models of human prostate cancer. The study [...]

Published
2003

6. Preclinical data on Mdm2 antisense oligonucleotide published

Subjects
Hybridon Inc., Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2003 OCT 31 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN) announced the publication of a paper on an Mdm2 antisense oligonucleotide in models of human prostate cancer. The study [...]

Published
2003

7. Preclinical data on Mdm2 antisense oligonucleotide published

Subjects
Hybridon Inc., Biotechnology industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2003 OCT 29 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN) announced the publication of a paper on an Mdm2 antisense oligonucleotide in models of human prostate cancer. The study [...]

Published
2003

8. Preclinical data on Mdm2 antisense oligonucleotide published

Subjects
Hybridon Inc., Biotechnology industry, Oncology
Abstract

2003 OCT 28 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN) announced the publication of a paper on an Mdm2 antisense oligonucleotide in models of human prostate cancer. The study [...]

Published
2003

9. Preclinical data on Mdm2 antisense oligonucleotide published

Subjects
Hybridon Inc., Biotechnology industry, Biotechnology industry, Business
Abstract

2003 OCT 27 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN) announced the publication of a paper on an Mdm2 antisense oligonucleotide in models of human prostate cancer. The study [...]

Published
2003

10. Preclinical data on Mdm2 antisense oligonucleotide published

Subjects
Hybridon Inc., Biotechnology industry
Abstract

2003 OCT 27 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN) announced the publication of a paper on an Mdm2 antisense oligonucleotide in models of human prostate cancer. The study [...]

Published
2003

11. Preclinical data on Mdm2 antisense oligonucleotide published

Subjects
Hybridon Inc., Biotechnology industry
Abstract

2003 OCT 27 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN) announced the publication of a paper on an Mdm2 antisense oligonucleotide in models of human prostate cancer. The study [...]

Published
2003

12. Hybridon Publishes Data on Novel Synthetic Agonists of Toll-Like Receptor 9

Subjects
Hybridon Inc., Biotechnology industry, Business, News, opinion and commentary
Abstract

CAMBRIDGE, Mass., May 11 /PRNewswire-FirstCall/ -- Hybridon, Inc. today announced the publication of results of preclinical studies on novel DNA compounds, designed by Hybridon, that activate TLR9 and induce distinct [...]

Published
2005

14. Hybridon Identifies Novel Synthetic Immunostimulatory Motif in Oligonucleotides that Overrides Specificity Across Animal Species; - Report Published in Proceedings of the National Academy of Sciences USA -

Subjects
Hybridon Inc., Biotechnology industry, Business, News, opinion and commentary
Abstract

Hybridon, Inc. (BULLETIN BOARD: HYBN.OB) today announced that it has identified a novel immunostimulatory motif in oligonucleotides that displayed potent activity in in vitro studies in immune cells obtained from [...]

Published
2003

15. Hybridon Antisense Technology Offers Promise in Breast Cancer Treatment

Subjects
Hybridon Inc., Biotechnology industry, Business, News, opinion and commentary
Abstract

New Study Published in Clinical Cancer Research Demonstrates Antisense Therapy Offers New Treatment Alternative WHAT: Hybridon, Inc. (OTC Bulletin Board: HYBN) and UAB (University of Alabama at Birmingham) study shows [...]

Published
2001

17. Data presented on synthetic agonists of toll-like receptor 9

Subjects
Hybridon Inc., Biotechnology industry, Drugs, Health, Science and technology
Abstract

Hybridon, Inc., (HBY) announced the publication of results of preclinical studies on novel DNA compounds, designed by Hybridon, that activate TLR9 and induce distinct immune responses. The results published in [...]

Published
2005

18. Data presented on synthetic agonists of toll-like receptor 9

Subjects
Hybridon Inc., Biotechnology industry, Drugs, Health
Abstract

Hybridon, Inc., (HBY) announced the publication of results of preclinical studies on novel DNA compounds, designed by Hybridon, that activate TLR9 and induce distinct immune responses. The results published in [...]

Published
2005

19. Data presented on synthetic agonists of toll-like receptor 9

Subjects
Hybridon Inc., Drugs, Biotechnology industries, Biotechnology industry
Abstract

Hybridon, Inc., (HBY) announced the publication of results of preclinical studies on novel DNA compounds, designed by Hybridon, that activate TLR9 and induce distinct immune responses. The results published in [...]

Published
2005

20. Latest preclinical study suggests broader potential utility of MDM2 antisense

Subjects
Hybridon Inc., Cytology, Biotechnology industry, Health, Pharmaceuticals and cosmetics industries
Abstract

2004 MAR 26 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HBY) announced the publication of a preclinical research report presenting evidence in cells and cell lysates that the MDM2 oncoprotein [...]

Published
2004

21. Latest preclinical study suggests broader potential utility of MDM2 antisense

Subjects
Hybridon Inc., Biotechnology industry, Cytology, Pharmaceuticals and cosmetics industries
Abstract

2004 MAR 26 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HBY) announced the publication of a preclinical research report presenting evidence in cells and cell lysates that the MDM2 oncoprotein [...]

Published
2004

22. Latest preclinical study suggests broader potential utility of MDM2 antisense

Subjects
Hybridon Inc., Biotechnology industry, Cytology, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2004 MAR 24 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HBY) announced the publication of a preclinical research report presenting evidence in cells and cell lysates that the MDM2 oncoprotein [...]

Published
2004

24. Latest preclinical study suggests broader potential utility of MDM2 antisense

Subjects
Hybridon Inc., Cytology, Biotechnology industry, Biotechnology industry, Business
Abstract

2004 MAR 22 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HBY) announced the publication of a preclinical research report presenting evidence in cells and cell lysates that the MDM2 oncoprotein [...]

Published
2004

27. Company identifies synthetic immunostimulatory motif in oligonucleotides

Subjects
Hybridon Inc., Biotechnology industry, Immunology, Health, Health care industry
Abstract

2004 JAN 4 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN.OB) has identified a novel immunostimulatory motif in oligonucleotides that displayed potent activity in in vitro studies in immune cells [...]

Published
2004

28. Company identifies synthetic immunostimulatory motif in oligonucleotides

Subjects
Hybridon Inc., Cell research, Biotechnology industry, Immunology, Pharmaceuticals and cosmetics industries
Abstract

2004 JAN 2 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN.OB) has identified a novel immunostimulatory motif in oligonucleotides that displayed potent activity in in vitro studies in immune cells [...]

Published
2004

29. Company identifies synthetic immunostimulatory motif in oligonucleotides

Subjects
Hybridon Inc., Cell research, Biotechnology industry, Immunology, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2003 DEC 31 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN.OB) has identified a novel immunostimulatory motif in oligonucleotides that displayed potent activity in in vitro studies in immune cells [...]

Published
2003

30. Company identifies synthetic immunostimulatory motif in oligonucleotides

Subjects
Hybridon Inc., Cell research, Biotechnology industry, Immunology
Abstract

2003 DEC 29 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN.OB) has identified a novel immunostimulatory motif in oligonucleotides that displayed potent activity in in vitro studies in immune cells [...]

Published
2003

31. Data presented on antitumor effects of immunomodulatory oligonucleotides

Subjects
Hybridon Inc., Biotechnology industry, Health, Pharmaceuticals and cosmetics industries
Abstract

2003 MAR 28 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN.OB) announced the presentation of preclinical studies of its immunomodulatory oligonucleotides (IMO) at the American Association for Cancer Research (AACR) [...]

Published
2003

32. Data presented on antitumor effects of immunomodulatory oligonucleotides

Subjects
Hybridon Inc., Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2003 MAR 28 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN.OB) announced the presentation of preclinical studies of its immunomodulatory oligonucleotides (IMO) at the American Association for Cancer Research (AACR) [...]

Published
2003

33. Data presented on antitumor effects of immunomodulatory oligonucleotides

Subjects
Hybridon Inc., Biotechnology industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2003 MAR 26 - (NewsRx.com & NewsRx.net) -- Hybridon, Inc., (HYBN.OB) announced the presentation of preclinical studies of its immunomodulatory oligonucleotides (IMO) at the American Association for Cancer Research (AACR) [...]

Published
2003

34. Antisense Therapy May Enhance Effects Of Chemotherapy

Subjects
Hybridon Inc., Biotechnology industry, Database industry, Biotechnology industry, Pharmaceuticals and cosmetics industries
Abstract

2001 DEC 12 - (NewsRx.com & NewsRx.net) -- Antisense therapy shows promise in attacking two types of breast cancer and can enhance the effects of standard chemotherapy, according to a [...]

Published
2001